Aristo Bio-Tech and Lifescience Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aristo Bio-Tech and Lifescience Limited's yearly results (2023–2026), compared with companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 92% of companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 92% of companies in India.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 87% of companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
1.9×Over the last 3 years its own operating cash covered its investment spending (capex) 1.9 times.
Higher than 67% of companies in India.
Cash Locked Ratio
₹13For every ₹100 of sales, ₹13 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹14 tied up three years earlier.
Less money tied up than 66% of companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 87% of companies in India.
Growth Efficiency Ratio
₹2Sales grew 67% in 3 years; of every extra ₹100 of sales, ₹2 became extra profit.
Lower than 73% of companies in India.
Asset Productivity Ratio
+67% / +55%In 3 years sales changed by +67% while total assets changed by +55%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.3×Debt due within a year is covered 0.3 times by its yearly operating cash.
Lower than 63% of companies in India.
Cash Cushion Ratio
−55%Debt, after subtracting cash, equals 55% of its market value (net debt).
Lower than 86% of companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 92% of companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 92% of companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Aristo Bio-Tech and Lifescience Limited owes ₹0.72 for every ₹1 it owns. Net profit rose 77% in the year to Mar 2026, and grew 26% a year on average over 3 years.
Compared with companies in India · latest annual results Mar 2026.
P/E ratio
8.5Investors pay ₹8.5 for every ₹1 of Aristo Bio-Tech and Lifescience Limited's yearly profit, lower than 89% of companies in India.
P/B ratio
1.36The share price is 1.36 times Aristo Bio-Tech and Lifescience Limited's book value per share, lower than 70% of companies in India.
Market cap
₹60 CrThe total market value of all of Aristo Bio-Tech and Lifescience Limited's shares at today's price (share price × number of shares), smaller than 93% of companies in India. PosiCap size class: Nano Cap.
Net worth (book value)
₹44 CrWhat Aristo Bio-Tech and Lifescience Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹64.79Net worth divided by the number of shares. The share price of ₹88.20 is 1.4 times this, which is the P/B above.
Owes vs Owns
0.72×Aristo Bio-Tech and Lifescience Limited owes ₹0.72 for every ₹1 it owns (moderate), higher than 87% of companies in India.
Revenue growth
+14%Revenue rose 14% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Profit growth
+77%Net profit rose 77% in the year to Mar 2026, and grew 26% a year on average over 3 years.
Profit margin
2.0%Aristo Bio-Tech and Lifescience Limited keeps ₹2 of every ₹100 of revenue as net profit.
Cash quality
1.2×Cash from Aristo Bio-Tech and Lifescience Limited's business was 1.2× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
5.2×Aristo Bio-Tech and Lifescience Limited's operating profit covered its interest costs 5.2 times in the year to Mar 2026.
Cash vs debt
Net debtAristo Bio-Tech and Lifescience Limited had ₹33 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Aristo Bio-Tech and Lifescience Limited's P/E ratio?
Investors pay ₹8.5 for every ₹1 of Aristo Bio-Tech and Lifescience Limited's yearly profit, lower than 89% of companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aristo Bio-Tech and Lifescience Limited: ₹60 Cr ÷ ₹44 Cr (31 Mar 2026) = 1.4.
How much does Aristo Bio-Tech and Lifescience Limited owe compared with what it owns?
Aristo Bio-Tech and Lifescience Limited owes ₹0.72 for every ₹1 it owns (moderate), higher than 87% of companies in India.
Is Aristo Bio-Tech and Lifescience Limited's revenue growing?
Revenue rose 14% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.